Free tool
FAERS Monitor: Hulio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761154 or its brand name (Hulio, Adalimumab-Fkjp). Reports on generic versions are filed under their own applications.
Reports
45,917
Serious
43,644
95% of reports
Hospitalization
16,237
Death reported
6,967
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,540
- off label use8,523
- rheumatoid arthritis5,848
- fatigue5,533
- pain5,476
- arthralgia5,246
- rash4,727
- condition aggravated4,537
- drug intolerance4,342
- systemic lupus erythematosus4,215
- joint swelling4,122
- diarrhoea4,107
- nausea4,106
- headache4,071
- treatment failure4,010
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 25 |
| 2006 | 10 |
| 2007 | 44 |
| 2008 | 136 |
| 2009 | 138 |
| 2010 | 257 |
| 2011 | 208 |
| 2012 | 256 |
| 2013 | 295 |
| 2014 | 277 |
| 2015 | 317 |
| 2016 | 504 |
| 2017 | 725 |
| 2018 | 1,253 |
| 2019 | 2,032 |
| 2020 | 2,712 |
| 2021 | 3,238 |
| 2022 | 4,580 |
| 2023 | 6,718 |
| 2024 | 8,378 |
| 2025 | 8,205 |
| 2026 | 5,601 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,008,242 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic lupus erythematosusSignal | 4,215 | 61.6 | 59.7 | 221,737 |
| rheumatoid arthritisSignal | 5,848 | 24.8 | 24.2 | 127,478 |
| treatment failureSignal | 4,010 | 23.2 | 22.6 | 81,548 |
| drug intoleranceSignal | 4,342 | 21.5 | 20.9 | 81,454 |
| joint swellingSignal | 4,122 | 16.2 | 15.7 | 56,931 |
| condition aggravatedSignal | 4,537 | 6.9 | 6.7 | 22,978 |
| arthralgiaSignal | 5,246 | 5.8 | 5.7 | 21,194 |
| rashSignal | 4,727 | 5.0 | 4.9 | 15,325 |
| off label useSignal | 8,523 | 4.5 | 4.4 | 23,908 |
| painSignal | 5,476 | 4.1 | 4.0 | 13,159 |
| drug ineffectiveSignal | 10,540 | 3.7 | 3.6 | 21,818 |
| fatigueSignal | 5,533 | 3.3 | 3.2 | 8,995 |
| headacheSignal | 4,071 | 3.0 | 2.9 | 5,509 |
| diarrhoeaSignal | 4,107 | 2.9 | 2.8 | 5,338 |
| nauseaSignal | 4,106 | 2.4 | 2.3 | 3,407 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.